Phase 2 Melanoma Trial, Recruiting NCT06548789 Sponsor: M.D. Anderson Cancer Center Condition: Melanoma
Back to Melanoma

Phase 2 Melanoma Trial, Recruiting

NCT06548789
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People with a body mass index (BMI) between 18.5 and 45 (a measure of body weight relative to height)
  • People who are able to complete study questionnaires tracking their diet and digestive symptoms on their own
  • People with a good to fully active level of physical functioning (confirm with trial site what this means for a specific situation)
  • People who have been diagnosed with a specific type and stage of skin melanoma (stage IIIB–D that can be surgically removed, or a limited spread of stage IV), or with melanoma affecting the mucous membranes (such as inside the mouth or nose), confirmed by a specialist team
  • People who are planned to start a standard treatment course using specific immunotherapy drugs (ipilimumab with or without nivolumab, or nivolumab with or without relatlimab) before surgery
  • People whose cancer can be measured using standard imaging criteria (confirm with trial site)
  • Women of childbearing potential who have a negative pregnancy test within one week of starting the dietary part of the study
  • People who are willing to eat the foods provided as part of the study (with some adjustments for personal food preferences)
  • People who are willing to attend scheduled visits, have blood drawn, and provide stool samples
  • People who have an existing tumour tissue sample available, or who are already planned to have a tumour biopsy as part of their standard treatment

Who may not be able to join:

  • People with a type of eye melanoma called uveal melanoma
  • People with a history of inflammatory bowel disease, removal of the entire large bowel, or weight-loss surgery on the stomach or bowel
  • People currently taking steroid medication at a dose higher than the equivalent of 10 mg per day of prednisone
  • People whose doctor determines the study diet is medically unsuitable for them
  • People with major dietary restrictions, including significant food allergies, coeliac disease, or who follow a vegan, ketogenic, or extended fasting diet
  • People with insulin-dependent diabetes, or who require a specific type of medication called bile-acid sequestrants
  • People who are unable or unwilling to take part in the study procedures
  • People who have received intravenous (IV) antibiotics more than once in the past month, or any antibiotic (IV or by mouth) in the past two weeks
  • People who regularly take supplements containing prebiotics, fibre, or probiotics and who are unwilling or unable to stop taking them for the study
  • People who currently smoke, drink more than 14 alcoholic drinks per week, or use illicit drugs
  • People who are currently pregnant, planning to become pregnant, or breastfeeding
  • People who have another cancer that requires systemic treatment (other than hormonal therapy)
  • People with cognitive impairment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Erez Baruch, MD,PHD, M.D. Anderson Cancer Center

Phone: 713-745-5530

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
16 September 2024
Est. completion
1 September 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

The completion rate, compliance and adherence.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov